Last reviewed · How we verify
Antiretroviral therapy plus Interleukin-2
This combination uses antiretroviral drugs to suppress HIV replication while interleukin-2 enhances immune cell proliferation and function to restore CD4+ T-cell counts.
This combination uses antiretroviral drugs to suppress HIV replication while interleukin-2 enhances immune cell proliferation and function to restore CD4+ T-cell counts. Used for HIV infection with CD4+ T-cell restoration.
At a glance
| Generic name | Antiretroviral therapy plus Interleukin-2 |
|---|---|
| Also known as | IL-2, Stavudine, Lamivudine, Indinavir |
| Sponsor | Juan A. Arnaiz |
| Drug class | Combination immunotherapy and antiviral |
| Target | HIV reverse transcriptase, protease, integrase (ART component); IL-2 receptor (IL-2 component) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Antiretroviral therapy (ART) directly inhibits HIV replication through various mechanisms (reverse transcriptase inhibition, protease inhibition, integrase inhibition, or entry inhibition). Interleukin-2 (IL-2) is a cytokine that stimulates proliferation and activation of T cells and natural killer cells, augmenting the immune response to control viral replication and restore immune competence in HIV-infected patients.
Approved indications
- HIV infection with CD4+ T-cell restoration
Common side effects
- Fever
- Fatigue
- Headache
- Nausea
- Immune activation syndrome
- Capillary leak syndrome (IL-2 related)
Key clinical trials
- HIV Reservoir Reduction With Interleukin-2 (PHASE2)
- CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients (PHASE1)
- Survival TRial Using CytoKines in COVID-19 (STRUCK Trial) (PHASE3)
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (PHASE3)
- Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People (PHASE2)
- Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems (PHASE1)
- Effect of Interleukin-2 on HIV Treatment Interruption (NA)
- Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiretroviral therapy plus Interleukin-2 CI brief — competitive landscape report
- Antiretroviral therapy plus Interleukin-2 updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI